Regulation of Inflammatory Parameters by Telmisartan in Hypertensive Patients

• Status: Completed
• Trial end date: 2009-10-01
• Target enrollment: 0
• Participant gender: All

Summary

A number of studies have shown that certain blood-pressure medications such as ACE-inhibitors and angiotensin-II-receptor blockers (ARB) can reduce the incidence of diabetes mellitus type

2. This protocol will evaluate whether inflammatory mechanisms mediate this effect. The investigators therefore will investigate the effect of telmisartan, a potent ARB, on lipid metabolism, glucose metabolism and inflammation in patients with the metabolic syndrome. Specific parameters will be tested before treatment and after 3 months of treatment. Placebo will be compared to 2 different doses of telmisartan per day.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Ludwig-Maximilians - University of Munich
• Collaborator: Bayer
• Treatments: Telmisartan

Criteria

Inclusion Criteria:

• Abd. obesity (BMI>25kg/m²) and waist circumference ≥95cm (men),≥80cm (women)

• Blood pressure ≥130 mmHg (systolic) and/or ≥85 mmHg (diastolic)

• Triglycerides 150-400 mg/dl

• Normal stress test

• Normal carotid ultrasound

• Normal fundoscopy

Exclusion Criteria:

• Diabetes mellitus

• Secondary cause for insulin resistance

• LDL-cholesterol >190 mg/dl

• Atherosclerotic disease

• Blood pressure >160 mmHg (systolic) and/or >100 mmHg (diastolic)

• Regular alcohol consumption (>30 g/day)

• Contraindication against telmisartan

• Antihypertensive medications

• Lipid lowering therapy

• Malignancy

• Pregnancy or Lactation

• Women without adequate contraception